Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance

Binswager, 2001, HIV/AIDS treatment for millions, Science, 292, 221, 10.1126/science.1057504

1998

Cohen, 2000, Companies, donors pledge to close gap in AIDS treatment, Science, 289, 368, 10.1126/science.289.5478.368

Adler, 1998, Antiretrovirals for developing world, Lancet, 351, 232, 10.1016/S0140-6736(05)78276-3

Gilks, 1997, The challenge of providing effective care for HIV/AIDS in Africa, AIDS, 11, S99

Colebunders, 1997, Antiretroviral treatment in Africa, AIDS, 11, S107

Farmer, 2001, Community-based approaches to HIV treatment in resource-poor settings, Lancet, 358, 404, 10.1016/S0140-6736(01)05550-7

Hertogs, 1998, A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs, Antimicrob Agents Chemother, 42, 269, 10.1128/AAC.42.2.269

Larder, 2000, Establishment of biologically-relevant cutoffs for HIV drug resistance testing, AIDS, 14, S111

Liang, 1986, Longitudinal data analysis using generalized linear models, Biometrics, 73, 13, 10.1093/biomet/73.1.13

Rubin, 1987

2000, AVANTI 2: randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naïve patients, AIDS, 14, 367, 10.1097/00002030-200003100-00009

Montaner, 1998, A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial, JAMA, 279, 930, 10.1001/jama.279.12.930

Hirsch, 1999, A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy, J Infect Dis, 180, 659, 10.1086/314948

Lucas, 1999, Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions, Ann Intern Med, 131, 81, 10.7326/0003-4819-131-2-199907200-00002

Republic of Uganda. The national strategic framework for HIV/AIDS activities in Uganda: 2000/1–2005/6. Republic of Uganda, 2000.

Henry, 1998, A randomized, controlled, doubleblind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS, J Acquir Immune Defic Syndr, 19, 339, 10.1097/00042560-199812010-00004

Hammer, 1997, A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less, N Engl J Med, 337, 725, 10.1056/NEJM199709113371101

Cameron, 1998, Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease, Lancet, 351, 543, 10.1016/S0140-6736(97)04161-5

Descamps, 2000, Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy, JAMA, 283, 205, 10.1001/jama.283.2.205

Romano, 2002, Development and significance of resistance to protease inhibitors in HIV-1 infected adults under triple-drug therapy in clinical practice, J Med Virol, 66, 143, 10.1002/jmv.2123

Carpenter, 2000, Antiretroviral therapy in adults: updated recommendations of the International AIDS Society- USA panel, JAMA, 283, 381, 10.1001/jama.283.3.381

Schoops, 2001, AIDS-drug price war breaks out in Africa, goaded by generics, Wall Street Journal, A1

2001